On July 21, 2022 Vivesto AB ("Vivesto" or the "Company"), an oncology-focused specialty pharmaceutical company, hereby reported that the Board of Directors of the Company today has appointed Christer Nordstedt as acting CEO of the Company (Press release, Vivesto, JUL 21, 2022, View Source [SID1234616868]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Christer assumes the position as acting CEO on 21 July 2022 and will hold the position until the recruitment of a permanent CEO is completed.
Peter Zonabend, Chairman of the Board of Vivesto, says: "We are very pleased to appoint Christer Nordstedt as acting CEO. Christer has a proven track record within R&D and his leadership ensures that we will achieve our goals. With his long and very relevant experience in R&D, Christer will be able to continue the strategic direction of Vivesto to become a strong oncology company through own development and future partnerships."
Christer Nordstedt is a Doctor of Medicine and has a PhD in Pharmacology and Biochemistry from the Karolinska Institute in Sweden and did his postdoctoral training with the Nobel laureate Paul Greengard at Rockefeller University in New York. Christer has many years of experience, including leading a large number of projects in the pharmaceutical industry from the earliest discovery all the way through clinical development, and has held positions such as Global Head of Specialty Research and Clinical Development and Senior Vice President Global Head of Clinical Development at Teva Pharmaceuticals, Head of R&D at Orion Cooperation as well as Senior Vice President at Hoffman-LaRoche in Basel and at Eli Lilly in Indianapolis. Currently, Christer is Chairman of the Board of WntResearch AB and engaged as a consultant at BioArctic AB. Christer does not own any shares or share-related instruments in Vivesto.